Merrill Matthews, Ph.D., is a resident scholar with the Institute for Policy Innovation, a research-based, public policy “think tank.” He is a health policy expert and opinion contributor at The Hill. He also serves on the Texas Advisory Committee of the U.S. Commission on Civil Rights.
Dr. Matthews is a past president of the Health Economics Roundtable for the National Association for Business Economics, the largest trade association of business economists. Dr. Matthews also served for 10 years as the medical ethicist for the University of Texas Southwestern Medical Center’s Institutional Review Board for Human Experimentation, co-author of On the Edge: America Faces the Entitlements Cliff, and has contributed chapters to several books, including Physician Assisted Suicide: Expanding the Debate and The 21st Century Health Care Leader and Stop Paying the Crooks (on Medicare fraud).
He has been published in numerous journals and newspapers, including The Wall Street Journal, Investor’s Business Daily, Barron’s, USA Today, Forbes magazine and the Washington Times. He was an award-winning political analyst for the USA Radio Network.
Dr. Matthews received his Ph.D. in Humanities from the University of Texas at Dallas.
Attempts to Stifle Debate By Far-Left House Members Are Reminiscent of McCarthy Era
Are congressional progressives misusing their office to scapegoat climate-change deniers?
Chris Christie Proves He Can Redistribute Money Like Barack Obama
Christie was in New Hampshire this week testing the presidential waters and decided to roll out a Social Security reform plan: Take money away from wealthier seniors and give it to lower-income seniors.
The High Cost of Inventing New Drugs--And of Not Inventing Them
The cost of developing new prescription drugs is very expensive—a process made even more expensive than it has to be because of excessive government restrictions and limited patent life. However, not developing new drugs can also be expensive, both in financial and human costs.
Rand Paul Is Right: We Should Scale Back Our $48 Billion In Foreign Aid
The question isn’t which countries receive U.S. foreign aid, but which ones DON’T get it?
The High Cost Of Inventing New Drugs -- And Of Not Inventing Them
If the cost of creating new drugs is high, the cost of not having any new drugs is immeasurable.
The Prescription Drug Act Works Well, and the President Can't Stand It
In Washington, nothing fails like success and nothing succeeds like failure. Just look at how some elected officials defend the worst health care law and criticize the best.
Eight Good Reasons To Abolish The IRS
Looking at the long list of IRS abuses, something needs to be done.
It's Time For States To Tell The Feds To Take Their Subsidies And Shove 'Em
It’s time to end the cycle of the feds taking our money only to hand some of it back—minus a big bureaucratic handling charge—if states do their bidding.
Medicare's Becoming A Means-Tested Welfare Program, And That Could Be A Good Thing
Those fighting to keep Medicare from becoming a means-tested welfare program are losing the battle, but that might be the only way we’re ever going to get real Medicare reform.
President Obama and Iran's Supreme Leader Have One Thing In Common: They're Not Believable
If Obama gets a deal, don’t be surprised if the agreement stresses ending the sanctions first and compliance verification second.
Total Records: 1735
